文献速递系统性红斑狼疮

美国商业保险与医疗补助保险人群中系统性红斑狼疮的经济负担

The economic burden of systemic lupus erythematosus in commercially- and medicaid-insured populations in the United States.
PubMed 文献 · Semin Arthritis Rheum · 2020-05-23

该研究基于IBM MarketScan数据库,纳入8231例商业保险和802例医疗补助保险的成人SLE患者,按疾病严重程度分层,评估12个月内的医疗利用与费用。商业保险中中度/重度SLE患者调整后平均总医疗费用(不含药房)显著高于轻度患者;医疗补助保险中该差异未达统计学显著,但医疗补助保险患者总未调整费用显著高于商业保险患者。

要点

  • 商业保险中67.4%为中度/重度SLE,医疗补助保险中74.8%为中度/重度SLE。
  • 商业保险中度/重度SLE调整后平均总费用(不含药房)$39,021 vs 轻度$23,519,p<0.0001。
  • 医疗补助保险中度/重度SLE调整后平均总费用$56,050 vs 轻度$44,932,p=0.06。

核心结论

  • 商业保险中治疗提示中度/重度SLE的患者调整后平均总医疗费用(不含药房)显著高于轻度SLE患者。
  • 医疗补助保险中中度/重度SLE患者费用高于轻度患者,但未达统计学显著。
  • 两种严重程度分层下,医疗补助保险患者的总未调整费用均显著高于商业保险患者。

研究设计与样本

  • 基于IBM MarketScan商业保险与医疗补助保险数据库的回顾性队列研究。
  • 纳入2010-2014年接受抗疟药、部分生物制剂、免疫抑制剂或全身糖皮质激素治疗的≥18岁SLE成人。
  • 以首次SLE药物索赔为索引日期,6个月暴露期后评估12个月内全因医疗利用与费用。
  • 商业保险8231例,医疗补助保险802例。

主要发现

  • 商业保险队列中轻度SLE占32.6%,中度/重度占67.4%。
  • 医疗补助保险队列中轻度SLE占25.2%,中度/重度占74.8%。
  • 商业保险中度/重度SLE调整后平均总医疗费用(不含药房)为$39,021,轻度为$23,519,p<0.0001。
  • 医疗补助保险中度/重度SLE调整后平均总医疗费用(不含药房)为$56,050,轻度为$44,932,p=0.06。

关键数值与推荐

  • 轻度SLE定义:抗疟药或糖皮质激素单药治疗且剂量≤5 mg/天。
  • 中度/重度SLE定义:糖皮质激素>5 mg/天、生物制剂、免疫抑制剂或联合治疗。

临床怎么用

  • 商业保险中治疗提示中度/重度SLE的患者医疗费用显著更高,提示需关注疾病严重程度对费用的影响。
  • 医疗补助保险患者总未调整费用显著高于商业保险患者,实施改善健康与降低支出的干预时应考虑支付方差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate the economic burden of systematic lupus erythematous (SLE), stratified by disease severity, in commercially- and Medicaid-insured US populations. METHODS: Adults (≥18 years) with SLE treated with antimalarials, selected biologics, immunosuppressants, and systemic glucocorticoids (2010-2014) were identified within the commercial and Medicaid insurance IBM MarketScan® databases (index date = first SLE medication claim). Both cohorts were stratified into mild (receiving antimalarial or glucocorticoid monotherapy ≤5 mg/day) versus moderate/severe SLE (receiving glucocorticoids >5 mg/day, biologic, immunosuppressant, or combination therapy) during a 6-month exposure period. All-cause healthcare utilization and costs were evaluated during the 12 months following the exposure period. RESULTS: Among 8231 commercially-insured patients, 32.6% had mild and 67.4% had moderate/severe SLE by our definition. Among 802 Medicaid-insured patients, 25.2% had mild and 74.8% had moderate/severe SLE. Adjusted mean total healthcare costs, excluding pharmacy, for moderate/severe SLE patients were higher than for mild SLE patients in the commercially-insured ($39,021 versus $23,519; p < 0.0001) and Medicaid-insured populations ($56,050 versus $44,932; p = 0.06). In both SLE severity populations total unadjusted costs were significantly higher among Medicaid-insured than commercially-insured patients. CONCLUSION: Commercially-insured patients with treatment suggesting moderate/severe SLE incurred significantly higher adjusted mean healthcare costs, excluding pharmacy, compared with mild SLE patients. While not reaching statistical significance, moderate/severe Medicaid-insured patients had higher costs then mild SLE patients. Total unadjusted healthcare costs were significantly higher among Medicaid-insured than commercially-insured patients. These differential costs are important to consider and monitor when implementing interventions to improve health and reduce healthcare spending for SLE.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Clarke AE, Yazdany J, Kabadi SM, et al. The economic burden of systemic lupus erythematosus in commercially- and medicaid-insured populations in the United States. Semin Arthritis Rheum. 2020. PMID: 32531505. doi:10.1016/j.semarthrit.2020.04.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。